Infectious Diseases in Obstetrics and Gynecology / 2018 / Article / Tab 1

Research Article

The Role of Polymorphonuclear Leukocyte Counts from Urethra, Cervix, and Vaginal Wet Mount in Diagnosis of Nongonococcal Lower Genital Tract Infection

Table 1

Unadjusted prevalence ratios (PRs) of microscopic inflammatory signs by sociodemographic, biological and behavioral characteristics, and clinical conditions.

CharacteristicsnTotal nPrev %PMNLs>5 (Urethral smear) PR (95% CI)pPMNLs>10 (Urethral smear) PR (95% CI)p PMNLs > epit. (Vag. wet mount) PR (95% CI)pPMNLs>30 (cervical smear) PR (95% CI)p

No regular partner23637563%0.89 (0.72-1.11)0.3020.86 (0.56-1.33)0.5020.93 (0.63-1.36)0.6950.63 (0.47-0.84) 0.002
Regular or cohabitant
partner last 6
13937537%1.11 (0.89-1.38)0.3361.16 (0.75 - 1.79)0.5021.09 (0.74-1.59)0.6671.59 (1.19-2.11)0.001
Partner>1 last 6 months27736775%1.26 (0.94-1.67)0.1090.96 (0.58 - 1.57)0.8581.08 (0.69-1.70)0.7331.23 (0.85-1.78)0.265
Condom use vaginal sex12235834%0.82 (0.64-1.04)0.1150.77 (0.47 - 1.24)0.2800.58 (0.36-0.92)0.0210.78 (0.56-1.10)0.170
Condom use last time4536312%1.06 (0.77-1.46)0.7010.99 (0.51 - 1.94)0.9810.95 (0.53-1.70)0.8671.01 (0.65-1.58)0.932
Symptoms of vaginal discharge19037550%0.81 (0.65-1.00)0.0590.79 (0.52 - 1.22)0.2931.56 (1.06-2.29)0.0241.07 (0.80-1.43)0.630
Dysuria7537520%1.29 (1.02-1.63)0.0302.00 (1.30 - 3.08)0.0020.98 (0.62-1.57)0.9441.13 (0.80-1.60)0.465
Warts3837510%1.07 (0.76-1.50)0.6810.13 (0.02 - 0.91)0.0400.55 (0.24-1.26)0.1581.24 (0.81-1.89)0.313
Cervical motion tenderness113753%1.99 (1.60-2.47)<0.0012.04 (0.90 - 4.59)0.0863.74 (2.59-5.4)<0.0011.71 (0.97-2.99)0.060
Mucopurulent endocervical exudate3637510%1.34 (1.01-1.78)0.0411.98 (1.18 - 3.33)0.0103.34 (2.38-4.69)<0.0012.42 (1.84-3.19)<0.001
Endocervical bleeding easily induced7337519%1.25 (0.99-1.59)0.0601.15 (0.69 - 1.92)0.5942.46 (1.72-3.51)<0.0011.53 (1.12-2.08)0.006
Cervical edema223756%1.17 (0.78-1.74)0.4281.25 (0.56 - 2.8)0.5813.67 (2.63-5.11)<0.0012.08 (1.46-2.95)<0.001
Without clinical finding for cervicitis12137532%0.80 (0.63-1.03)0.0960.86 (0.53 - 1.38)0.5220.32 (0.18-0.58)<0.0010.81 (0.58-1.12)0.215
Chlamydia trachomatis3937510%1.84 (1.50-2.25)<0.0013.27 (2.17 - 4.94)<0.00011.82 (1.16-2.85)0.0092.00 (1.46-2.72)<0.001
Mycoplasma genitalium163724%1.07 (0.65-1.78)0.7671.39 (0.58 - 3.34)0.4611.37 (0.65-2.91)0.4111.57 (0.94-2.63)0.082
Mycoplasma hominis9037524%1.02 (0.79-1.31)0.8531.29 (0.81 - 2.05)0.2771.04 (0.67-1.60)0.8720.90 (0.63-1.28)0.561
Ureaplasma urealyticum9137524%1.04 (0.82-1.33)0.7531.19 (0.74 - 1.90)0.4791.37 (0.92-2.04)0.1181.35 (1.00-1.84)0.049
Ureaplasma parvum29937580%1.34 (0.97-1.84)0.0661.50 (0.81 - 2.79)0.2011.31 (0.78-2.19)0.3030.85 (0.60-1.19)0.358
Vaginal candidiasis6937119%1.10 (0.84-1.43)0.4681.66 (1.05 - 2.63)0.0301.95 (1.34-2.85)0.0011.21 (0.85-1.71)0.280
pH>4.514837040%1.00 (0.81-1.25)0.9320.96 (0.62 - 1.49)0.8701.39 (0.96-2.01)0.0851.25 (0.93-1.67)0.133
Whiff pos Amine test10536529%1.03 (0.81-1.31)0.7731.18 (0.75 - 1.87)0.4661.37 (0.93-2.01)0.1131.04 (0.75-1.44)0.793
Double infection CT/MG/UU203755%1.42 (1.01-.00)0.0462.33 (1.3 - 4.17)0.0051.82 (1.03-3.22)0.0411.75 (1.14-2.69)<0.001
Previous STD17433652%0.83 (0.66-1.04)0.1101.16 (0.74 - 1.82)0.5070.99 (0.67-1.47)0.9471.16 (0.85-1.60)0.336

PMNL: polymorphonuclear leukocyte, Positive NAAT, and pseudohyphae in vaginal KOH wet mount.
Significant values in bold.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.